News

Adcetris is an antibody-drug conjugate (ADC) directed to CD30, a determining marker of Hodgkin lymphoma. The ADC includes an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to

An anti-von Willebrand factor (vWF) nanobody, Caplacizumab met both the primary endpoint and key secondary endpoints of the phase 3 trial, dubbed HERCULES. The late-stage trial evaluated it against

Endocyte intends to move quickly into Phase 3 development of 1 Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of

Hundreds of thousands of Americans could be protected from or treated for Ebola infections through the first purchase of vaccines and therapeutic drugs by the Biomedical Advanced Research

The FDA’s decision on approval is anticipated to be taken by 28 January 2018. Roche’s supplemental Biologics License Application (sBLA), which was accepted by the FDA, is based

This decision was made based on a review of available Phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options

The Pennsylvania-based specialty pharmaceutical company said that the phase 2 study FAB-C had met its primary endpoint by recording an improvement by 46% at week twelve in the

"Novartis pioneers new therapeutic paradigms, creating definitive medicines for life-threatening diseases," said Jay Bradner, President of the Novartis Institutes for BioMedical Research. "Our Berkeley alliance powerfully extends our

Tricida plans to report topline results from this study in the second quarter of 2018. If successful, TRCA-301 will serve as the pivotal trial for the submission of